You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 29, 2025

Claims for Patent: 3,923,785

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 3,923,785

Title:	(R)-3-(2-deox y-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,][1,3]diaz epin-8-ol
Abstract:	Essentially pure (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[ 4,5-d][1,3]-diazepin-8-ol and the process for the production of (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[ 4,5-d][1,3]diazepin-8-ol by inoculating an aqueous nutrient medium, preferably containing sources of assimilable carbon and nitrogen and added inorganic salt and having a pH between about 6 and 8, with a (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[ 4,5-d][1,3]diazepin-8-ol producing strain of Streptomyces antibioticus, such as the strain corresponding to NRRL 3238, conducting a fermentation under aseptic aerobic conditions at a temperature between about 20 and 45.degree.C. until a substantial quantity of (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo- [4,5-d][1,3]diazepin-8-ol is formed, and isolating the desired product from the fermentation mixture are disclosed. The (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[ 4,5-d][1,3]diazepin-8-ol potentiates the activity of 9-(.beta.-D-arabinofuranosyl)adenine as an antiviral agent that is active in vitro and in vivo against DNA viruses such as herpes and vaccinia viruses.
Inventor(s):	Ryder; Albert (Detroit, MI), Dion; Henry W. (Detroit, MI), Woo; Peter W. (Ann Arbor, MI), Howells; John D. (Grosse Pointe Woods, MI)
Assignee:	Parke, Davis & Company (Detroit, MI)
Application Number:	05/462,826
Patent Claims:	1. An essentially pure compound having the name (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[ 4,5-d][1,3]diazepin-8-ol. 2. A mixture consisting of the compound of claim 1 and 9-(.beta.-D-arabinofuranosyl)adenine. 3. The mixture of claim 2 wherein the ratio of (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[ 4,5-d][1,3]diazepin-8-ol to 9-(.beta.-D-arabinofuranosyl)adenine is from about 0.005 to 0.2:1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.